Extracellular proteases are involved in important stages of cancer malignancy. Cysteine cathepsins, particularly cathepsin L, B and S, have been implicated in many of these processes.
VBY-825 is a potent, competitive and reversible inhibitor of multiple cathepsins. It exhibits picomolar or low nanomolar potency on all cathepsins commonly implicated in cancer, and is considered a pan-cathepsin protease inhibitor.
VBY-825 has demonstrated potent efficacy in a spontaneous tumor model with effects on primary tumor burden and tumor vasculature.